# Yuce Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/yuce-bio

- Industry: Biotechnology
- Headquarters: Shenzhen, China
- Website: www.yucebio.com
- Total disclosed funding: $44M
- Latest round: Series C (Aug 25, 2020)
- Investors on record: 3

## About

Based in Shenzhen, China and established in 2015, Yuce Bio is a tumor immune diagnosis and treatment platform that focuses on the detection technology of tumor neoantigens to carry out product development, transformation, and commercial promotion. The company provides clinical medication guidance, dynamic monitoring and testing products for tumor patients. Also, it provides companion diagnosis and treatment target development service for pharmaceutical companies, based on the company's tumor neoantigen detection and identification platform, tumor immune multi-dimensional detection and research platform, tumor bio-information interpretation database, tumor immune diagnosis and treatment real-world research database. It's business covered more than 40 cities, and 200 hospitals.

The company provides tumor clinical testing and clinical research, pharmaceutical R&D services, companion diagnosis-in vitro diagnostic reagents (CDx-IVD). 

The company plans to continue develop clinical precision diagnosis, and immunological drug development, around tumor immunity. Also, it will build a tumor immunity diagnosis platform, based on privacy computing and data security.

## Funding rounds

- Series C, Aug 25, 2020, $44M — Puhua Capital
- Series B, Dec 10, 2018 — IDG Capital
- Series A, Mar 16, 2018 — Shenzhen Huada Gene Technology Co., Ltd., Puhua Capital

## Investors

- Shenzhen Huada Gene Technology Co., Ltd. — Series A
- Puhua Capital (https://capitalatlas.ai/funds/puhua-capital) — Series A, Series C
- IDG Capital (https://capitalatlas.ai/funds/idg-capital) — Series B